Going To The Angels: Independent Investors Back $16M Series B For Savara
This article was originally published in The Pink Sheet Daily
Executive Summary
Savara Pharmaceuticals will finance an 80-patient Phase II trial for its inhaled vancomycin candidate as a treatment for MRSA infections in cystic fibrosis patients. Such infections have been linked with a six-year reduction in life expectancy.